Comparative Pharmacology
Head-to-head clinical analysis: AMINOSYN 5 versus AMINOSYN II 10 W ELECTROLYTES.
Peer-Reviewed Evidence
Head-to-head clinical analysis: AMINOSYN 5 versus AMINOSYN II 10 W ELECTROLYTES.
AMINOSYN 5% vs AMINOSYN II 10% W/ ELECTROLYTES
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Aminosyn 5% provides essential and nonessential amino acids for protein synthesis, maintaining nitrogen balance, and supporting tissue repair in patients unable to tolerate oral intake.
Amino acids serve as substrates for protein synthesis and nitrogen balance; electrolytes maintain osmotic and acid-base balance.
Intravenous infusion; 500 mL of 5% solution (25 g protein equivalent) per day, typically at a rate not exceeding 100 mL/hour. Dosage individualized based on protein requirements and metabolic status.
1-2 g/kg/day (0.1-0.2 g/kg/hour) IV via central line as continuous infusion.
None Documented
None Documented
Not applicable as a drug; amino acids have rapid turnover with half-lives varying from minutes to hours depending on the individual amino acid.
The terminal elimination half-life of individual amino acids varies but is generally short (range 0.5–2 hours) due to rapid uptake and metabolism. Clinically, the half-life of infused amino acids is not a relevant parameter for dosing; rather, infusion rate is adjusted to maintain nitrogen balance.
Amino acids are metabolized; nitrogen is excreted renally as urea (80-90%) and in feces (5-10%).
Amino acids are primarily metabolized to urea and other nitrogenous waste products, which are excreted renally (90-95% of total nitrogen excreted as urea). Unmetabolized amino acids in plasma are also filtered and reabsorbed by the kidneys; negligible amounts are excreted unchanged (<5%). Biliary/fecal excretion is minimal (<2%).
Category C
Category C
Amino Acid Solution
Amino Acid Solution